Inactive Instrument

Other languages SoftOx Solutions AS Oslo Bors

Equities

NO0010811961

Other languages

Unlock all the news: Be the first to know and act before the market!

SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	03-19
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10-31
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	26/09/23
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023	21/06/23
Oslo Børs Places Seven Issuers in Penalty Bench over Public Disclosure Rule Violations	02/06/23
Softox Solutions AS Announces Resignation of Kari Myren from the Board	24/03/23
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	15/02/23
Softox Solutions Announces Signing of the Final Grant Agreement for the Counteract Consortium	09/01/23
SoftOx Solutions AS Appoints Christian Harstad as the Interim Chief Executive Officer	20/12/22
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	15/12/22
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	26/10/22
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products	19/10/22
SoftOx Solutions AS Announces Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	04/10/22
SoftOx Solutions AS Announces the End of the SBE Phase 1 Clinical Study for Treatment of Chronic Wounds	05/09/22
SoftOx Solutions AS Announces Executive Changes in its Subsidiary, SoftOx Defense Solutions AS	01/09/22
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22
SoftOx Solutions AS Announces Clinical Trial Data Published in Acta Dermato-Venereologica	28/06/22
SoftOx Solutions AS Announces Positive Phase 1 Results for SoftOx Inhalation Solution	19/05/22
SoftOx Solutions AS Announces the Last Patient Completes the Last Single-Dose Cohort of the SBE-01 Clinical Study	11/05/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages SoftOx Solutions AS Oslo Bors

Equities

NO0010811961

Other languages

Filters